1 April 2023 in Radiology
Background Neurodegenerative disorders (such as Alzheimer disease) characterized by the deposition of various pathogenic forms of tau protein in the brain are collectively referred to as tauopathies. Identification of the molecular drivers and pathways of neurodegeneration is critical to individualized targeted treatment of these disorders. However, despite important advances in fluid biomarker detection, characterization of these molecular subtypes is limited by the blood-brain barrier. Purpose To evaluate the feasibility and safety of focused ultrasound-mediated liquid biopsy (sonobiopsy) in the detection of brain-derived protein biomarkers in a transgenic mouse model of tauopathy (PS19 mice). Materials and Methods Sonobiopsy was performed by sonicating the cerebral hemisphere in 2-month-old PS19 and wild-type mice, followed by measurement of plasma phosphorylated tau (p-tau) species (30 minutes after sonication in the sonobiopsy group). Next, spatially targeted sonobiopsy was performed by sonicating either the cerebral cortex or the hippocampus in 6-month-old PS19 mice. To detect changes in plasma neurofilament light chain (a biomarker of neurodegeneration) levels, blood samples were collected before and after sonication (15 and 45-60 minutes after sonication). Histologic staining was performed to evaluate tissue damage after sonobiopsy. The Shapiro-Wilk test, unpaired and paired t tests, and the Mann-Whitney U test were used. Results In the 2-month-old mice, sonobiopsy significantly increased the normalized levels of plasma p-tau species compared with the conventional blood-based liquid biopsy (p-tau-181-to-mouse tau [m-tau] ratio: 1.7-fold increase, P = .006; p-tau-231-to-m-tau ratio: 1.4-fold increase, P = .048). In the 6-month-old PS19 mice, spatially targeted sonobiopsy resulted in a 2.3-fold increase in plasma neurofilament light chain after sonication of the hippocampus and cerebral cortex (P < .001). After optimization of the sonobiopsy parameters, no excess microhemorrhage was observed in the treated cerebral hemisphere compared with the contralateral side. Conclusion This study showed the feasibility of sonobiopsy to release phosphorylated tau species and neurofilament light chain to the blood circulation, potentially facilitating diagnosis of neurodegenerative disorders. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Fowlkes in this issue.
1 October 2021 in The Journal of the Acoustical Society of America
MRI-guided focused ultrasound combined with microbubbles has been used in clinical studies for blood-brain barrier (BBB) opening. However, the impact of the static magnetic field generated by an MRI scanner on the BBB opening outcome has not been evaluated. The objective of this study was to determine the relationship of the static magnetic field of an MRI scanner on focused ultrasound combined with microbubble-induced BBB opening. Mice were divided into four groups which were sonicated by FUS in different static magnetic fields B0 (∼0T, 1.5T, 3.0T, and 4.7T) with all other experimental parameters kept the same. Microbubble cavitation activity was monitored by passive cavitation detection during FUS after microbubble injection. After sonication, contrast-enhanced T1-weighted MRI and Evans blue were used to evaluate the BBBO outcome. The microbubble cavitation dose decreased by an average of 2.1 dB at 1.5T (P = 0.05), 2.9 dB at 3.0T (Pi = 0.01), and 3.0 dB at 4.7T (P = 0.01) compared with that outside the magnetic field. It also decreased Evans blue trans-BBB delivery 1.4-fold at1.5T (P = 0.009), 1.6-fold at 3.0T (P < 0.001), and 1.9-fold at 4.7T (P < 0.001). These findings demonstrated that static magnetic fields dampened microbubble cavitation and decreased trans-BBB delivery by FUS.